Poland· PL-100325911
Gazyvaro
A obinutuzumab product containing obinutuzumabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Obinutuzumab is registered in 2 of 19 countries.
Countries holding a registration under ATC L01XC15 (obinutuzumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Obinutuzumab · ATC L01XC15
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Obinutuzumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01XC15
- ATC class
- Obinutuzumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05902768001105
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for obinutuzumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Obinutuzumab · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Obinutuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandGazyvaroAbacus Medicine A/S
- BelgiumGazyvaro 1000 mgRoche Registration
- CzechiaGAZYVARORoche Registration GmbH, Grenzach-Wyhlen
- IcelandGazyvaroRoche Registration GmbH*
- NorwayGazyvaroRoche Registration GmbH
- SwedenGazyvaro 1000 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- SpainGAZYVARO 1000 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United KingdomGazyvaro 1000mg/40ml concentrate for solution for infusion vialsOriginalis B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Gazyvaro
- Liechtenstein · Gazyvaro
- Norway · Gazyvaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc5d8d89-81bf-4598-b2ea-a936d218befa GET /v1/drugs/dc5d8d89-81bf-4598-b2ea-a936d218befa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "1000 mg",
"packaging": "05902768001105 ¦ Rpz ¦ EU/1/14/937/001 ¦ 104024\n1 fiol. 40 ml",
"substance": "Obinutuzumabum 1000 mg",
"common_name": "Obinutuzumabum",
"pl_product_id": "100325911",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about obinutuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.